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Background: Baroreflex activation therapy (BAT) modulates sympathovagal balance, which is deranged in patients with heart failure leading to 
increased morbidity and mortality. Our aim was to study the effect of BAT on levels of the prognostic markers NTproBNP, NYHA class and 6-Minute 
Walk Test in patients with heart failure and reduced ejection fraction. 
methods: 6 Patients were implanted with the CVRx neoTM system (CVRx Inc., Minneapolis, Minnesota) at the University of Cologne as part of a 
first-in-man study of BAT for systolic heart failure. They had an ejection fraction of <35% and were in NYHA class III before BAT (inclusion criteria). 
NTproBNP measurements and 6-Minute Walk Tests were performed prior to implantation and repeatedly during follow-up. NTproBNP was quantified 
as the average of all available values within 3 month before implantation and after activation of the device. All data are presented as mean±SEM. 
results: NTproBNP was 2797±971 ng/l prior to BAT and fell to 1352±322 ng/l during an average follow-up of 7.1 months (p<0.05). 6-Minute 
Walk Distance improved from 314±42 m to 367±25 m (p<0.05). NYHA class decreased from 3.0±0.0 to 2.7±0.2 (p=0.08). There were no serious 
adverse events with definite or probable relation to the procedure or device. 
conclusions: These preliminary, first-in-man data indicate that BAT significantly lowers levels of NTproBNP in patients with systolic heart failure 
and improves 6-Minute Walk Test and NYHA functional class at least in trend. These findings suggest that BAT may improve clinical status and 
possibly prognosis in heart failure patients. These promising initial results encourage pursuing the study of BAT in patients with heart failure.
